Last 32 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.80 | — | — | 5.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.96 | 61.80 | 51.99 | 1.28 | 1354.83 | 3458.16 | 3215.24 | 75116.66 | 50045.32 | 58019.25 | 14016.12 | — | 6.66 | 724.60 | 471.91 | 144.65 | 130.19 | 348.19 | 99.95 | 1611.06 | 133.38 |
| — | -98.2% | -98.4% | -100.0% | -97.3% | -94.0% | -77.1% | — | +751761.1% | +7907.1% | +2870.1% | — | -94.9% | +108.1% | +372.1% | -91.0% | -2.4% | +3053.7% | -30.9% | — | — | |
| P/B Ratio | 1.40 | 2.29 | 1.40 | 0.86 | 1.32 | 0.49 | 0.38 | 0.59 | 1.09 | 1.97 | 2.61 | 2.58 | 1.63 | 2.13 | 2.57 | 3.12 | 1.04 | 0.83 | 1.65 | 1.86 | 3.25 |
| — | +365.1% | +265.9% | +46.0% | +21.7% | -75.0% | -85.3% | -77.2% | -33.4% | -7.4% | +1.6% | -17.4% | +57.4% | +157.3% | +56.3% | +67.9% | -68.2% | -69.1% | -65.5% | -56.9% | — | |
| P/FCF | — | — | — | 3.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 5.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 9.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.1% | 44.8% | 32.6% | 97.7% | -52386.7% | -319573.3% | -290607.1% | -178300.0% | -1282700.0% | -637100.0% | -99435.7% | 137089.5% | -24.1% | -9767.8% | -7420.8% | -1624.1% | -3688.0% | -12506.2% | -1489.9% | -18952.2% | -1059.6% |
| — | +100.0% | +100.0% | +100.1% | +95.9% | +49.8% | -192.3% | -230.1% | -5330158.3% | -6422.5% | -1240.0% | +8540.8% | +99.3% | +21.9% | -398.1% | +91.4% | -248.1% | -283473.8% | -176.7% | -1463.3% | -1802.1% | |
| Operating Margin | -187.2% | -2037.2% | -2416.1% | 17.3% | -67983.3% | -396373.3% | -383007.1% | -5611700.0% | -1704400.0% | -849120.0% | -136200.0% | 192905.3% | -69.2% | -13446.0% | -10102.7% | -2303.1% | -5299.0% | -17546.9% | -2165.1% | -26917.4% | -1658.9% |
| — | +99.5% | +99.4% | +100.0% | +96.0% | +53.3% | -181.2% | -3009.0% | -2464170.0% | -6215.0% | -1248.2% | +8475.8% | +98.7% | +23.4% | -366.6% | +91.4% | -219.4% | -33580.1% | -165.5% | -1387.7% | -1475.1% | |
| Net Margin | -164.4% | -1929.0% | -2256.6% | 22.8% | -63195.6% | -364386.7% | -342657.1% | -4967100.0% | -1461433.3% | -699060.0% | -115717.9% | 169910.5% | -50.8% | -12391.6% | -9624.8% | -2195.6% | -5138.2% | -17337.0% | -2160.6% | -27264.1% | -1628.0% |
| — | +99.5% | +99.3% | +100.0% | +95.7% | +47.9% | -196.1% | -3023.4% | -2878879.5% | -5541.4% | -1102.3% | +7838.7% | +99.0% | +28.5% | -345.5% | +91.9% | -215.6% | -33207.9% | -163.4% | -1396.4% | -1442.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.6% | -17.0% | -14.4% | 4.4% | -14.4% | -12.3% | -9.8% | -9.3% | -7.7% | -5.9% | -7.1% | -10.1% | -3.1% | -10.9% | -12.7% | -11.3% | -9.8% | -9.9% | -8.6% | -9.2% | -9.6% |
| — | -38.3% | -46.8% | +147.5% | -87.4% | -108.7% | -37.2% | +7.7% | -145.4% | +46.0% | +44.0% | +10.7% | +68.1% | -10.3% | -48.9% | -22.8% | -2.5% | -214.4% | -30.2% | +26.6% | +38.8% | |
| ROA | -24.9% | -14.5% | -12.7% | 3.9% | -12.7% | -11.0% | -8.9% | -8.5% | -7.2% | -5.6% | -6.7% | -9.2% | -2.9% | -9.9% | -11.3% | -10.1% | -8.8% | -8.9% | -7.8% | -8.4% | -9.0% |
| — | -31.3% | -42.9% | +145.9% | -76.9% | -97.6% | -33.4% | +7.3% | -149.4% | +43.7% | +41.1% | +8.9% | +67.4% | -11.0% | -46.0% | -19.6% | +1.8% | -209.5% | -32.1% | +20.6% | -12.5% | |
| ROIC | -28.1% | -14.9% | -12.7% | 2.7% | -12.9% | -12.3% | -10.8% | -10.8% | -9.5% | -8.5% | -13.9% | -38.5% | -12.1% | -18.5% | -12.9% | -12.1% | -11.8% | -10.3% | -9.4% | -11.8% | -26.1% |
| — | -21.3% | -18.2% | +125.1% | -35.5% | -44.9% | +22.2% | +71.8% | +20.8% | +54.3% | -7.7% | -217.1% | -1.8% | -79.4% | -36.4% | -3.2% | +54.7% | — | — | — | -36.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.10 | 0.05 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.04 | 0.02 | 0.02 | 0.05 | 0.05 | 0.05 | 0.07 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 | — |
| — | +75.5% | -10.5% | -12.1% | +34.3% | +136.2% | +115.2% | +1.1% | -2.2% | -51.7% | -67.1% | -31.6% | -30.2% | -22.9% | +26.3% | +35.2% | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | 1.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.39 | 8.03 | 9.34 | 9.39 | 8.42 | 8.75 | 12.36 | 14.92 | 17.33 | 28.48 | 32.65 | 15.65 | 18.07 | 23.11 | 18.36 | 14.02 | 17.14 | 17.20 | 20.10 | 15.69 | 14.57 |
| — | -8.2% | -24.5% | -37.1% | -51.4% | -69.3% | -62.1% | -4.7% | -4.1% | +23.2% | +77.9% | +11.6% | +5.4% | +34.4% | -8.7% | -10.6% | +17.6% | -31.7% | +5.8% | -7.1% | +124.8% | |
| Quick Ratio | 9.39 | 8.03 | 9.34 | 9.39 | 8.42 | 8.75 | 12.36 | 14.92 | 17.33 | 28.48 | 32.65 | 15.65 | 18.07 | 23.11 | 18.36 | 14.02 | 17.14 | 17.20 | 20.10 | 15.69 | 14.57 |
| — | -8.2% | -24.5% | -37.1% | -51.4% | -69.3% | -62.1% | -4.7% | -4.1% | +23.2% | +77.9% | +11.6% | +5.4% | +34.4% | -8.7% | -10.6% | +17.6% | -31.7% | +5.8% | -7.1% | +124.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -79.37 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FDMT stock.
4D Molecular Therapeutics, Inc.'s current P/E is -4.8x. The average P/E over the last 1 quarters is 5.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
4D Molecular Therapeutics, Inc.'s current operating margin is -187.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking 4D Molecular Therapeutics, Inc.'s business trajectory between earnings reports.